Daniel Rose

Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.

SpineVision SA develops and markets implants for the treatment of spinal disorders. It also designs instrumentation for the spinal treatments. Its products include Flex 2, Lumis, Plus/X-Plus, ULIS, Unithread, Spacevisions, and C3. The firm also offers solutions for spinal pathologies, such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma, and tumors. The company was founded by Gérard Vanacker on July 16, 1999 and is headquartered in Antony, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

Cryolog SA provides traceability software solutions. The company was founded by Renaud Vaillant in 2002 and is headquartered in Nantes, France.

Exane Asset Management SA (Exane AM) is an alternative investment management firm headquartered in Paris, France. The firm was founded in 2001 and is a subsidiary of Exane SA, itself a subsidiary of BNP Paribas SA (EPA: BNP) in France. Exane AM manages a range of long/short equity market neutral funds designed to respond to the varied needs of a diversified European clientele, composed chiefly of institutional investors, multi-fund managers and private banking professionals.

Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France.

Barts & The London NHS Trust provides health care services in hospitals. Its services include air ambulance, hepatology, anaesthetics and pain management, haematology, paediatric respiratory, emergency department, endocrinology, Urology, and many more. The company is headquartered in Aldgate, the United Kingdom.

MD Start SA develops medical device technology. It has collaboration between venture capital, institutional investors and industry to the development of innovative medtech ideas in Europe. The company was founded by Tim Lenihanin 2010 and is headquartered in Paris, France.

HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

UroMems SASdesigns and develops implantable medical devices. Its product is an active implantable medical device which compensates for sphincter insufficiency with the help of a MyoElectroMechanical System. The company was founded by Hamid Lamraoui in 2011 and is headquartered in Grenoble, France.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.

Guard Medical, Inc. creates products that aim to improve the quality of life for surgical patients. The company is based in Miami, FL and was founded by Machiel van der Leest, J. Frederick Cornhill, Laurence Lefebvre, Sang Lee. The company is behind NPseal, a negative pressure wound therapy dressing that is easy to use and does not require batteries or tubes. The dressing features a simple pinch pump that applies and maintains gentle negative pressure that may promote wound healing. Numerous peer-reviewed studies have demonstrated the utility of NPWT in reducing wound healing time.

Moon Surgical SAS is a French medical technology company that is creating a new category of robotic surgery. The company is based in Paris, France and is operated by renowned serial medical innovators and backed by leading venture capitalists. Its Maestro system enhances existing laparoscopic techniques and tools with new capabilities, benefiting the 93%% of patients who currently do not have access to minimally invasive robotic surgery. The CEO of the company is Anne Osdoit.

Société Coopérative Agricole Interface Céréales SCA engages in the development of sustainable agriculture. It provides animal feeds, fertilizers, agricultural chemicals, and other farm supplies. The company was founded in December 2005 and is headquartered in Dreux, France.